Lunar, Hologic and Norland dual-energy X-ray absorptiometry scanners have been compared for measurements of spine and femur bone density. Precision was not greatly different in realistic phantoms and volunteer subjects. Most clinical therapeutic trials are concerned with measuring changes of bone mineral, and interchangeability in this context was examined using phantoms of spine and femur in which changes of bone mineral density (BMD) were simulated. With each instrument the measured changes were closely linear. For the spine the biggest difference of slope between instruments was 15%. For the femur, in all areas of interest, the differences of slope were less than 10%. It is concluded that the three instruments can be satisfactorily used in multicentre clinical trials to investigate changes in bone mineral. 12 volunteers were measured with each scanner. There were significant mean differences between each pair of instruments, suggesting different calibration criteria. More importantly, those mean differences had appreciable standard deviations (SDs), in proportional terms from 3% to 10%. When the measurements were related to reference ranges and expressed in terms of age-matched normal values the mean biases disappeared, but the SDs did not improve. Results from different manufacturers' apparatus are not interchangeable for studying individual patients. Measurements from the phantoms were used to cross-calibrate the scanners. Those from the variable spine phantom predicted the in vivo ratio within 4%, but this was no better than measurements of the unmodified phantom alone. Results using the European Spine Phantom were less satisfactory. No phantom provided an adequate cross-calibration for femur measurements.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1259/0007-1285-68-810-621 | DOI Listing |
Expert Rev Hematol
January 2025
Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Objective: Deep vein thrombosis (DVT) is a known complication of fractures. This study aimed to explore the genetic causal relationship between DVT and fracture sites.
Research Design And Methods: The exposures analyzed in this study included fracture of femur (FFE), fracture of lower leg, including ankle (FLLA), fracture of shoulder and upper arm (FSUA), fracture of forearm (FFO), fracture of rib, sternum and thoracic spine (FRSTS) and fracture of lumbar spine and pelvis (FLSP).
Cells
January 2025
Linda and Mitch Hart Center for Regenerative and Personalized Medicine, Steadman Philippon Research Institute, Vail, CO 81657, USA.
Duchenne muscular dystrophy (DMD) is a severe genetic muscle disease occurring due to mutations of the dystrophin gene. There is no cure for DMD. Using a dystrophinutrophin (DKO-Hom) mouse model, we investigated the PGE2/EP2 pathway in the pathogenesis of dystrophic muscle and its potential as a therapeutic target.
View Article and Find Full Text PDFClin Nucl Med
January 2025
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
A 54-year-old man presented with a 1-month history of pain and numbness in the right lower limb. Lumbar spine MRI revealed bone metastases. 18F-FDG PET/CT showed a soft tissue mass with increased 18F-FDG uptake in the rectum, accompanied by multiple hypermetabolic lesions in the bilateral ribs, spine, pelvis, and upper right femur.
View Article and Find Full Text PDFFront Surg
January 2025
Department of Orthopedics, Dokuz Eylul University, Izmir, Türkiye.
Ureteral papillary carcinoma is a rare subtype of urothelial carcinoma, ranking fourth among cancers following prostate (or breast) cancer, lung cancer, and colorectal cancer. Although previous studies have documented bone metastases mainly in the pelvis, spine, ribs, and femur, this case report presents the first recorded instance of metastasis occurring in the acromioclavicular joint. A 62-year-old woman with a history of left flank pain and macroscopic hematuria underwent a left nephroureterectomy, which revealed ureteral papillary carcinoma.
View Article and Find Full Text PDFLupus Sci Med
January 2025
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Objective: Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.
Methods: A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!